OpGen

OpGen Current Liabilities

The Current Liabilities of OpGen (OPGN) as of Oct 19, 2026 is 4.55 M USD. In the previous year, Current Liabilities was 543,896.00 USD — a change of 737.13% (higher).

Current Liabilities

4.55 MUSD

YoY

737.13%

Last updated:

Current Liabilities of OpGen is 2025 4.55 M USD. Current Liabilities of OpGen was 2024 543,896.00 USD. It decreases by 737.13% higher compared to the previous year.

The OpGen Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
7.11 M USD
Jan 1, 2019
8.80 M USD
Jan 1, 2020
12.86 M USD
Jan 1, 2021
38.53 M USD
Jan 1, 2022
20.48 M USD
Jan 1, 2023
22.68 M USD
Jan 1, 2024
543,896.00 USD
Jan 1, 2025
4.55 M USD
The OpGen Current Liabilities history
YEARCurrent LiabilitiesYoY
4.55 MUSD+737.13%
543,896.00USD-97.60%
22.68 MUSD+10.76%
20.48 MUSD-46.85%
38.53 MUSD+199.69%
12.86 MUSD+46.05%
8.80 MUSD+23.84%
7.11 MUSD+4.09%
6.83 MUSD-5.33%
7.21 MUSD+6.17%
6.79 MUSD-5.72%
7.21 MUSD+98.87%
3.62 MUSD-4.49%
3.79 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Current Liabilities of OpGen is 4.55 M USD in 2025.

Current Liabilities of OpGen changed from 543,896.00 USD to 4.55 M USD, representing a 737.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities OpGen since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen